Work

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Year: 2007

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.07.5754

Authors: David M. Jackman, Beow Y. Yeap, Neal I. Lindeman, Panos Fidias, Michael S. Rabin, Jennifer Temel, Arthur T. Skarin, Matthew Meyerson, Alison J. Holmes, Ana M. Borras, Boris Freidlin, Patricia A. Ostler, Joan Lucca, Thomas J. Lynch, Bruce E. Johnson, Pasi A. Jänne

Institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Cancer Institute

Awards: EGFR Mutations in Non-Small Cell Lung Cancer, G4847968760, SPORE in Lung Cancer, G6108898346, G6316124, Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

OpenAlex ID: W2106585301

FWCI: 35.91

Cites: 37

Cited by: 307

Related to: 10